Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?

Inhibition of Tumor Necrosis Factor-α–Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor-γ With Nuclear Factor κB and CCAAT/Enhancer-Binding Protein-β

(2009) Qingping Tian et al.   HYPERTENSION

The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies

(2009) Fabrizio Montecucco et al.   MEDIATORS OF INFLAMMATION

Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo

(2009) M. Ekholm et al.   THROMBOSIS RESEARCH

Molecule-specific Effects of Angiotensin II-Receptor Blockers Independent of the Renin-Angiotensin System

(2008) T. W. Kurtz et al.   AMERICAN JOURNAL OF HYPERTENSION

Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice

(2008) Erwin Blessing et al.   ATHEROSCLEROSIS

T cells in arteritis and atherosclerosis

(2008) Cornelia M Weyand et al.   CURRENT OPINION IN LIPIDOLOGY

The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control

(2008) Akiko Yamana et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Telmisartan but Not Candesartan Affects Adiponectin Expression In Vivo and In Vitro

(2008) Satoru Yamada et al.   HYPERTENSION RESEARCH

Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Improves Coronary Microcirculation and Insulin Resistance among Essential Hypertensive Patients without Left Ventricular Hypertrophy

(2008) Toshihide Hinoi et al.   HYPERTENSION RESEARCH

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

(2008) Shiho NAKAYAMA et al.   HYPERTENSION RESEARCH

Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-??-modulating activity, on nitric oxide bioavailability and atherosclerotic change

(2008) Hideyuki Ikejima et al.   JOURNAL OF HYPERTENSION

Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives

(2008) Ramiro A Sanchez et al.   JOURNAL OF HYPERTENSION

Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation

(2008) Elena Kaschina et al.   JOURNAL OF HYPERTENSION

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy

(2008) George Bakris et al.   KIDNEY INTERNATIONAL

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

(2008)   LANCET

Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance

(2008) Shinji Makita et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

(2008) J. Galle et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

(2008) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telmisartan Inhibits Advanced Glycation End Products (AGEs)-Elicited Endothelial Cell Injury by Suppressing AGE Receptor (RAGE) Expression Via Peroxisome Proliferator-Activated Receptor-γ Activation

(2008) Sho-ichi Yamagishi et al.   PROTEIN AND PEPTIDE LETTERS

Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells

(2007) Silvana Cianchetti et al.   ATHEROSCLEROSIS

Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats

(2007) Q Dai et al.   BRITISH JOURNAL OF PHARMACOLOGY

Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor

(2007) M T Le et al.   BRITISH JOURNAL OF PHARMACOLOGY

Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-γ

(2007) Daniel Walcher et al.   HYPERTENSION